Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004074 · ClinicalTrials.gov registry record · Phase 1
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00004074: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00004074 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004074, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Phase I trial to study the effectiveness of interleukin-12 and trastuzumab in treating patients who have cancer that has high levels of HER2/neu and has not responded to previous therapy
Interventions
- BIOLOGICAL recombinant interleukin-12
- BIOLOGICAL ABI-007/carboplatin/trastuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 1999-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004074
The ClinicalTrials.gov registry entry for NCT00004074 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which recombinant interleukin-12 is the first listed.
NCT00004074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004074 about?
NCT00004074 is a clinical study titled "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu". Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells...
What is the current status of trial NCT00004074?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 1999-08.
What interventions are being tested in trial NCT00004074?
The interventions under investigation include: recombinant interleukin-12 (BIOLOGICAL), ABI-007/carboplatin/trastuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004074?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.